Molecule Details
| InChIKey | VRQXRVAKPDCRCI-ZNMIVQPWSA-N |
|---|---|
| Compound Name | Lgh-447 |
| Canonical SMILES | C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 9.48 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB14943 |
|---|---|
| Drug Name | LGH-447 |
| CAS Number | 1210608-43-7 |
| Groups | investigational |
| ATC Codes | nan |
| Description | LGH-447 is under investigation in clinical trial NCT02160951 (Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies). |
Cross-references: BindingDB: 106870 CHEMBL3651966 ChemSpider: 34957627 PDB: 5H7 ZINC: ZINC000116907270
Target Activities (3)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| Q9P1W9 | PIM2 | Serine/threonine-protein kinase pim-2 | modulator | targets |